Silk fibroin-derived nanoparticles for biomedical applications

Nanomedicine

Volumn 5, Issue 5, 2010, Pages 807-820

  Mathur, Anshu B ^a   Gupta, Vishal ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

antiparallel pleated sheets; biodegradable; cancer cells; nanoparticles; quantum dots; silk fibroin

Indexed keywords

ANTINEOPLASTIC AGENT; CHITOSAN; CISPLATIN; CURCUMIN; DOXORUBICIN; EMODIN; ETOPOSIDE; LIPOSOME; NANOCARRIER; NANOCOATING; NANOPARTICLE; NUTRACEUTICAL; PACLITAXEL; POLYMER; PROTEIN TYROSINE KINASE; QUANTUM DOT; SILK FIBROIN; TELOMERASE REVERSE TRANSCRIPTASE; VIRUS PROTEIN;

ANTINEOPLASTIC ACTIVITY; BETA SHEET; BIOCOMPATIBILITY; BIOMEDICAL ENGINEERING; BREAST CANCER; CANCER CELL; CELL VACUOLE; CHEMICAL COMPOSITION; CLINICAL TRIAL; COLORECTAL TUMOR; CONTROLLED DRUG RELEASE; CYTOTOXICITY; DOWN REGULATION; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; KELOID; LIVER TUMOR; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN ASSEMBLY; REVIEW; SKIN FIBROBLAST; SOLID TUMOR; SUSTAINED DRUG RELEASE; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; BOMBYX; DRUG DELIVERY SYSTEMS; FIBROINS; HUMANS; NANOPARTICLES; NEOPLASMS;

EID: 77954944881     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.10.51     Document Type: Review

References (80)

1. Allen TM, Cullis PR: Drug delivery systems: entering the mainstream. Science 303(5665), 1818-1822 (2004).
2. Grantab R, Sivananthan S, Tannock IF: The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res. 66(2), 1033-1039 (2006).
3. Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ: Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin. Cancer Res. 8(3), 878-884 (2002).
4. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK: Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64(11), 3731-3736 (2004).
5. Cheema SK, Gobin AS, Rhea R, Lopez-Berestein G, Newman RA, Mathur AB: Silk fibroin mediated delivery of liposomal emodin to breast cancer cells. Int. J. Pharm. 341(1-2), 221-229 (2007).
6. Gobin AS, Rhea R, Newman RA, Mathur AB: Silk-fibroin-coated liposomes for long-term and targeted drug delivery. Int. J. Nanomed. 1(1), 81-87 (2006).
7. Gregoriadis G: Liposomes as a drug delivery system: optimization studies. Adv. Exp. Med. Biol. 238, 151-159 (1988).
8. Gregoriadis G: Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol. 13(12), 527-537 (1995).
9. Gupta V, Aseh A, Rios CN, Aggarwal BB, Mathur AB: Fabrication and characterization of silk fibroin-derived curcumin nanoparticles for cancer therapy. Int. J. Nanomed. 4, 115-122 (2009).
10. Lasic DD: Novel applications of liposomes. Trends Biotech. 16(7), 307-321 (1998).
11. Yoshioka T, Skalko N, Gursel M, Gregoriadis G, Florence AT: A non-ionic surfactant vesicle-in-water-in-oil (v/w/o) system: potential uses in drug and vaccine delivery. J. Drug Target. 2(6), 533-539 (1995).
12. Kundu J, Chung Y, Kim YH, Tae G, Kundu SC: Silk fibroin nanoparticles for cellular uptake and control release. Int. J. Pharm. 388, 242-250 (2010).
13. Zhang Y-Q, Shen W-D, Xiang R-L, Zhuge L-J, Gao W-J, Wang W-B: Formation of silk fibroin nanoparticles in water-miscible organic solvent and their characterization. J. Nano. Res. 9, 885-900.
14. Decuzzi P, Godin B, Tanaka T etal.\ Size and shape effects in the biodistribution of intravascularly injected particles. J. Control. Release 141(3), 320-327 (2010).
15. Tasciotti E, Liu X, Bhavane R et at.: Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat. Nanotechnol. 3(3), 151-157.
16. Gabizon A, Martin F: Polyethylene glycol-coated (PEGylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 54(Suppl. 4), 15-21 (1997).
17. Tong R, Yala L, Fan TM, Cheng J: The formulation of aptamer-coated paclitaxel- polylactide nanoconjugates and their targeting to cancer cells. Biomaterials 31(11), 3043-3053 (2010).
18. Silk Polymers Materials Science and Biotechnology. Kaplan DL, Adams WW, Farmer B, Viney C (Eds). American Chemical Society, Washington DC, USA (1994).
19. Santin M, Motta A, Freddi G, Cannas M: In vitro evaluation of the inflammatory potential of the silk fibroin. J. Biomed. Mat. Res. 46(3), 382-389 (1999).
20. Ha SW, Tonelli AE, Hudson SM: Structural studies of Bombyx mori silk fibroin during regeneration from solutions and wet fiber spinning. Biomacromol. 6(3), 1722-1731 (2005).
21. Ha SW, Gracz HS, Tonelli AE, Hudson SM: Structural study of irregular amino acid sequences in the heavy chain of Bombyx mori silk fibroin. Biomacromolecules 6(5), 2563-2569 (2005).
22. Ha SW, Asakura T, Kishore R: Distinctive influence of two hexafluoro solvents on the structural stabilization of Bombyx mori silk fibroin protein and its derived peptides: 13c NMR and CD studies. Biomacromol. 7(1), 18-23 (2006).
23. Wound Closure Biomaterials. Chu CC, Fraunhofer JA, Greisler HP (Eds). CRC Press LLC, Salem, MA, USA (1997).
24. Pecha ER, Prindiville T, Kotfila R, Ruebner B, Cheung AT, Trudeau W: Gastrointestinal hemorrhage consequent to foreign body reaction to silk sutures: case series and review. Gastrointest. Endosc. 48(3), 299-301 (1998).
25. Aramwit P, Kanokpanont S, De-Eknamkul W, Srichana T: Monitoring of inflammatory mediators induced by silk sericin. J. Biosci. Bioeng. 107(5), 556-561 (2009).
26. Altman GH, Diaz F, Jakuba C etal.: Silk-based biomaterials. Biomaterials 24(3), 401-416 (2003).
27. Zhou C-Z, Confalonieri F, Jacquet M, Perasso R, Li Z-G, Janin J: Silk fibroin: structural implications of a remarkable amino acid sequence. Proteins 44(2), 119-122 (2001).
28. Falini G, Weiner S, Addadi L: Chitin-silk fibroin interactions: relevance to calcium carbonate formation in invertebrates. Calcif. Tissue Int. 72(5), 548-554 (2003).
29. Roden L, Koerner T, Olson C, Schwartz NB: Mechanisms of chain initiation in the biosynthesis of connective tissue polysaccharides. Fed. Proc. 2(44), 373-380 (1985).
30. Yeo J-H, Lee K-G, Lee Y-W, Kim SY: Simple preparation and characteristics of silk fibroin microsphere. Eur. Pol. J. 39(6), 1195-1199 (2003).
31. Wenk E, Wandrey AJ, Merkle HP, Meinel L: Silk fibroin spheres as a platform for controlled drug delivery. J. Control. Release 132(1), 26-34 (2008).
32. Wang X, Wenk E, Matsumoto A, Meinel L, Li C, Kaplan DL: Silk microspheres for encapsulation and controlled release. J. Control. Release 117(3), 360-370 (2007).
33. Wang X, Hu X, Daley A, Rabotyagova O, Cebe P, Kaplan DL: Nanolayer biomaterial coatings of silk fibroin for controlled release. J. Control. Release 121(3), 190-199 (2007).
34. Wang X, Wenk E, Hu X et al.: Silk coatings on PLGA and alginate microspheres for protein delivery. Biomaterials 28, 4161-4169 (2007).
35. Wang X, Yucel T, Lu Q, Hu X, Kaplan DL: Silk nanospheres and microspheres from silk/ pva blend films for drug delivery. Biomaterials 31(6), 1025-1035 (2010).
36. Yan H-B, Zhang Y-Q, Ma Y-L, Zhou L-X: Biosynthesis of insulin-silk fibroin nanoparticles conjugates and in vitro evaluation of a drug delivery system. J. Nano. Res. 11, 1937-1946 (2009).
37. Caldon CE, Daly RJ, Sutherland RL, Musgrove EA: Cell cycle control in breast cancer cells. J. Cell. Biochem. 97(2), 261-274 (2006).
38. Jayasuriya H, Koonchanok NM, Geahlen RL, McLaughlin JL, Chang CJ: Emodin, a protein tyrosine kinase inhibitor from Polygonum cuspidatum. J. Nat. Prod. 55(5), 696-698 (1992).
39. Majsterek I, Pytel D, Blasiak J: Tyrosine kinases. New target of anticancer therapy. Postepy. Biochem. 51(3), 251-260 (2005).
40. Wakeling AE: Inhibitors of growth factor signalling. Endocr. Relat. Cancer 12(Suppl. 1), S183-S187 (2005).
41. Zhang L, Chang CJ, Bacus SS, Hung MC: Suppressed transformation and induced differentiation of Her-2/neu-overexpressing breast cancer cells by emodin. Cancer Res. 55(17), 3890-3896 (1995).
42. Zhang L, Lau YK, Xi L et al.: Tyrosine kinase inhibitors, emodin and its derivative repress Her-2/neu-induced cellular transformation and metastasis-associated properties. Oncogene 16(22), 2855-2863 (1998).
43. Zhang L, Lau YK, Xia W, Hortobayagi GN, Hung MC: Tyrosine kinase inhibitor emodin suppresses growth of Her-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin. Cancer Res. 5(2), 343-353 (1999).
44. Hung MC, Lau YK: Basic science of Her-2/ neu: a review. Sem. Oncology 26(4 Suppl. 12), 51-59 (1999).
45. Siegel PM, Ryan ED, Cardiff RD, Muller WJ: Elevated expression of activated forms of neu/ erbb-2 and erbb-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J. 18(8), 2149-2164 (1999).
46. Dhillon N, Aggarwal BB, Newman RA et al.: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 14(14), 4491-4499 (2008).
47. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB: Bioavailability of curcumin: problems and promises. Mol. Pharm. 4(6), 807-818 (2007).
48. Muthenna P, Suryanarayana P, Gunda SK, Petrash JM, Reddy GB: Inhibition of aldose reductase by dietary antioxidant curcumin: mechanism of inhibition, specificity and significance. FEBSLett. 583(22), 3637-3642 (2009).
49. Slonim AE, Grovit M, Bulone L: Effect of exclusion diet with nutraceutical therapy in juvenile Crohn's disease. J. Am. Coll. Nutr. 28(3), 277-285 (2009).
50. Kunnumakkara AB, Anand P, Aggarwal BB: Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 269(2), 199-225 (2008).
51. Bisht S, Feldmann G, Soni S et al.: Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J. Nanobiotechnol. 5, 3 (2007).
52. Sahu A, Bora U, Kasoju N, Goswami P: Synthesis of novel biodegradable and self-assembling methoxy poly(ethylene glycol) -palmitate nanocarrier for curcumin delivery to cancer cells. Acta Biomater. 4(6), 1752-1761 (2008).
53. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MN: Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared with curcumin administered with piperine as absorption enhancer. Eur. J. Pharm. Sci. 37(3-4), 223-230 (2009).
54. Tiyaboonchai W, Tungpradit W, Plianbangchang P: Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int. J. Pharm. 337(1-2), 299-306 (2007).
55. Chen C, Johnston TD, Jeon H et al.: An in vitro study of liposomal curcumin: stability, toxicity and biological activity in human lymphocytes and Epstein-Barr virus- transformed human p-cells. Int. J. Pharm. 366(1-2), 133-139 (2009).
56. Kunwar A, Barik A, Pandey R, Priyadarsini KI: Transport of liposomal and albumin loaded curcumin to living cells: an absorption and fluorescence spectroscopic study. Biochim. Biophys. Acta 1760(10), 1513-1520 (2006).
57. Li L, Braiteh FS, Kurzrock R: Liposome- encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104(6), 1322-1331 (2005).
58. Sou K, Inenaga S, Takeoka S, Tsuchida E: Loading of curcumin into macrophages using lipid-based nanoparticles. Int. J. Pharm. 352(1-2), 287-293 (2008).
59. Garcea G, Berry DP, Jones DJ et al.: Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol. BiomarkersPrev. 14(1), 120-125 (2005).
60. Garcea G, Jones DJ, Singh R et al.: Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br. J. Cancer 90(5), 1011-1015 (2004).
61. Aggarwal BB, Shishodia S, Takada Y et al.: Curcumin suppresses the paclitaxel-induced nuclear factor-kB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin. Cancer Res. 11(20), 7490-7498 (2005).
62. Hong RL, Spohn WH, Hung MC: Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin. Cancer Res. 5(7), 1884-1891 (1999).
63. Inano H, Onoda M, Inafuku N et al.: Potent preventive action of curcumin on radiation- induced initiation of mammary tumorigenesis in rats. Carcinogenesis 21(10), 1835-1841 (2000).
64. Somers-Edgar TJ, Scandlyn MJ, Stuart EC, Le Nedelec MJ, Valentine SP, Rosengren RJ: The combination of epigallocatechin gallate and curcumin suppresses ER a-breast cancer cell growth in vitro and in vivo. Int. J. Cancer 122(9), 1966-1971 (2008).
65. Myung SJ, Kim H-S, Kim Y, Chen P, Jin H-J: Fluorescent silk fibroin nanoparticles prepared using reverse microemulsion. Macromol. Res. 16(7), 604-608 (2008).
66. Prasad CP, Rath G, Mathur S, Bhatnagar D, Ralhan R: Potent growth suppressive activity of curcumin in human breast cancer cells: modulation of wnt/p-catenin signaling. Chem. Biol. Interact. 181(2), 263-271 (2009).
67. Ramachandran C, Fonseca HB, Jhabvala P, Escalon EA, Melnick SJ: Curcumin inhibits telomerase activity through human telomerase reverse transcritpase in MCF-7 breast cancer cell line. Cancer Lett. 184(1), 1-6 (2002).
68. Nathwani BB, Jaffari M, Juriani AR, Mathur AB, Meissner KE: Fabrication and characterization of silk-fibroin-coated quantum dots. IEEE Trans. Nanobioscience 8(1), 72-77 (2009).
69. Chang SQ, Dai YD, Kang B, Han W, Chen D: g-radiation synthesis of silk fibroin coated CDSE quantum dots and their biocompatibility and photostability in living cells. J. Nanosci. Nanotechnol. 9(10), 5693-5700 (2009).
70. Damm E-M, Pelkmans L, Kartenbeck J, Mezzacasa A, Kurzchalia T, Helenius A: Clathrin- and caveolin-1-independant endocytosis: entrin of simian virus 40 into cells devoid of caveolae. J. Cell Biol. 168(3), 477-488 (2005).
71. Cerf E, Sarroukh R, Tamamizu-Kato S et al.: Antiparallel p-sheet: a signature structure of the oligomeric amyloid p-peptide. Biochem. J. 421, 415-423 (2009).
72. Argos P: A possible homology between immunodeficiency virus p24 core protein vp2 coat protein: prediction of HIV p24 antigenic sites. EMBOJ. 8(3), 779-785 (1989).
73. Gobin AS, Froude VE, Mathur AB: Structural and mechanical characteristics of silk fibroin and chitosan blend scaffolds for tissue regeneration. J. Biomed. Mat. Res. 74A(3), 465-473 (2005).
74. Gobin AS, Butler CE, Mathur AB: Repair and regeneration of the abdominal wall musculofascial defect using silk fibroin- chitosan blend. Tissue Eng. 12(12), 3383-3394 (2006).
75. Rios CN, Skoracki RJ, Miller MJ, Satterfield WC, Mathur AB: In vivo bone formation in silk fibroin and chitosan blend scaffolds via ectopically grafted periosteum as a cell source: a pilot study. Tissue Eng. 15(9), 2717-2725 (2009).
76. DeFife KM, Shive MS, Hagen KM, Clapper DL, Anderson JM: Effects of photochemically immobilized polymer coatings on protein adsorption, cell adhesion, and foreign body reaction to silicone rubber. J. Biomed. Mater. Res. 44(3), 298-307 (1999).
77. Grayson ACR, Voskerician G, Lynn A, Anderson JM, Cima MJ, Langer R: Differential degradation rates in vivo and in vitro of biocompatible poly(lactic acid) and poly(glycolic acid) homo- and co-polymers for a polymeric drug-delivery microchip. J. Biomater. Sci. Pol. Ed. 15(10), 1281-1304 (2004).
78. Sheng Y, Liu C, Yuan Y et al.: Long- circulating polymeric nanoparticles bearing a combinatorial coating of PEG and water- soluble chitosan. Biomaterials 30(12), 2340-2348 (2009).
79. Zustiak SP, Durbal R, Leach JB: Influence of cell-adhesive peptide ligands on poly(ethylene glycol) hydrogel physical, mechanical, and transport properties. Acta Biomaterialia (2010) (Epub ahead of print).
80. NIH clinical trial data